Nicolas Fraunhoffer is a biomedical researcher specializing in translational oncology and pancreatic cancer, with a focus on treatment resistance, tumor heterogeneity, and precision medicine. His research integrates multi-omics, patient-derived models, and perturbation approaches to model and target resistant tumor populations. A central aspect of his work is the development of transcriptomic signatures to characterize tumor phenotypes and predict therapeutic response. He has contributed to studies on drug repurposing, KRAS inhibition, and mechanisms of resistance in pancreatic cancer, with the broader goal of translating biological insights into clinically relevant therapeutic strategies.